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Background: Differentiated thyroid carcinoma (DTC) originates from thyroid follicular epithelial cells and belongs to
a group of slowly progressing tumors with a relatively good prognosis. However, recurrences and metastases are a
serious problem in advanced stages. Furthermore, progression from a well differentiated thyroid carcinoma to an
aggressive anaplastic one is possible.
The majority of differentiated thyroid carcinomas are sporadic but a few alleles increasing the cancer risk are
known. One of them is the c.470 T > C (p.I157T, rs17879961) missense substitution in the CHEK2 gene.
Aim of the study: The aim of this study was to investigate whether this specific CHEK2 alteration, c.470 T > C,
predisposes the Great Poland (Wielkopolska) population to thyroid cancer.
Methods: 602 differentiated thyroid carcinoma patients and 829 controls randomly selected from population were
genotyped for the presence of the c.470C allele using pyrosequencing. Hardy-Weinberg Equilibrium (HWE) was
tested for both groups by chi-square distribution and Fisher’s exact test. The odds ratios (ORs), 95% confidence
intervals (CIs), and p-values were calculated using the R software.
Results: The results of genotyping showed the presence of the c.470C allele in 51 patients with a frequency of
4.49%, while in a controls in 42 patients with a frequency of 2.53%. We demonstrated that in the Great Poland
population the c.470C CHEK2 variant increases the risk of developing differentiated thyroid cancer almost twice
(OR = 1.81, p = 0.004). The risk of papillary thyroid carcinoma in female patients homozygous for the c.470C allele
was shown to increase almost 13-fold (OR = 12.81, p = 0.019).
Conclusions: Identification of c.470C CHEK2 gene variant ought to be taken into account by healthcare
policymakers. Future well-designed and larger population studies are of great value in confirming these findings.
Moreover, a combination of genetic factors together with environmental exposures should also be considered.
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Differentiated thyroid carcinoma (DTC) originates from
thyroid follicular cells and is the most common malig-
nancy of the endocrine system. In the Polish population,
it accounts for almost 1.5% of all cancers. The most fre-
quently occuring differentiated thyroid carcinoma types
are papillary thyroid carcinoma (PTC; 65-90% of cases),
follicular carcinoma (FTC; 10%-35%), and Hurthle cell
or oxyphilic tumors (5%). More than 2,000 new cases of
differentiated thyroid carcinoma are reported in Poland
each year (2389 cases in 2011) [1]. The majority of pa-
tients are women. Generally, in various populations thy-
roid cancer occurs approximately four to six times less
frequently in males, which indicates different molecular
backgrounds between the two genders [2].
The etiology of thyroid cancer is not well understood
except for a few percent of cases that are inherited or
are a part of some cancer syndromes. However, in most
cases thyroid cancer results from an interaction of sev-
eral environmental (chemical agents, irradiation, iodine
deficiency) and genetic factors [3]. Iodine intake plays a
particular role in the pathogenesis of thyroid cancer.
The papillary thyroid carcinoma is more often observed
in areas of sufficient iodine diet content, while follicular
thyroid carcinoma appears more frequently in areas of
iodine deficiency. In Poland, during the fifteen years
following the introduction of iodine prophylaxis, the fol-
licular thyroid carcinoma frequency has decreased,
whereas the incidence of papillary thyroid carcinoma
and lymphocytic infiltration due to autoimmune thyroid-
itis has increased significantly [4].
Most studies show that papillary thyroid carcinoma
and follicular thyroid carcinoma patients have similar
prognoses [5], but some authors reported significant
differences in the behavior of follicular and papillary
thyroid carcinomas, even though they are derived from
the same follicle cells [6]. Papillary thyroid carcinomas
tend to grow very slowly and usually develop in only
one lobe of the thyroid gland. They often spread to the
lymph nodes in the neck but still have a good progno-
sis. Follicular thyroid carcinomas usually metastasize to
distant tissues: lungs or bones. In advanced stages, they
do not give such a favorable prognosis as papillary thyroid
carcinomas. For unclear reasons, certain histological sub-
types of papillary thyroid carcinoma may have a poor prog-
nosis, similar to that of highly invasive forms of follicular
carcinoma [7,8].
The clinical evaluation of thyroid nodules is based on
a detailed medical history, a physical examination and
laboratory tests. Ultrasound examination with fine nee-
dle aspiration biopsy (FNAB) may improve the accuracy
of cytological diagnosis and patient management [9],
however, 30% of diagnoses using these methods remain
inconclusive [10]. Researchers underline the necessity toidentify and validate novel markers of increased thyroid
cancer susceptibility [11]. Multiple studies on low
penetrance cancer susceptibility alleles showed that
alterations in the CHEK2 gene increase the risk of dif-
ferent malignancies [12].
The CHEK2 gene (22q12.1) encodes the human ortho-
logue of the yeast checkpoint kinases Cds1 and Rad53.
The CHEK2 protein is activated by phosphorylation in
response to DNA damage and it inhibits the CDC25C
phosphatase, thus preventing mitosis. It stabilizes the
p53 tumor suppressor protein, which induces the arrest
of the cell cycle in the G1 phase [13]. Falck and collabo-
rators suggested that the ATM-CHEK2-CDC25A-CDK2
pathway is a genomic checkpoint that prevents the syn-
thesis of DNA damaged by ionizing radiation [14]. In
the early stages of tumorigenesis, human cells activate
an ATR/ATM-regulated DNA damage response path-
way, which delays the progression of cancer. Mutations
in the ATM-CHEK2-p53 pathway lead to uncontrolled
cell proliferation, high genomic instability, tumor cell
evasion from apoptosis, and tumor progression [15]. It
has been shown that four alterations in the CHEK2 gene,
1100delC, IVS2 + 1G > A, del5395, and c.470 T > C pre-
dispose the Polish population to various cancers [16].
The most frequent of these is missense change c.470 T >
C (p.I157T, rs17879961) with an incidence of 5 per 100
persons in the European populations [12,16,17]. This
alteration is localized in a region coding for a function-
ally important FHA domain of the CHEK2 protein. The
protein with a threonine in the 157 position is defective
in its ability to bind p53, BRCA1 and Cdc25A proteins
[14,18,19]. This altered CHEK2 protein may also have a
dominant negative effect by forming heterodimers with
the wild-type form [17].
The aim of this study was to determine whether the
c.470 T > C (p.I157T, rs17879961) CHEK2 allele increases
the susceptibility to differentiated thyroid carcinoma in
the Great Poland population.Materials and methods
Patients and controls
We analyzed material from 602 patients with differentiated
thyroid carcinoma (527 females and 75 males) from the
Great Poland region. All of them were diagnosed at the
Department of Endocrinology, Metabolism, and Internal
Diseases of the Poznan University of Medical Sciences.
The group consisted of 535 patients diagnosed with
papillary thyroid carcinoma and 67 patients with fol-
licular thyroid carcinoma. In the examined group we
did not record family history of thyroid cancers, how-
ever we noticed two familial cases of papillary thyroid
carcinoma. Furthermore in 26 patients we observed
also other primary cancers (Table 1).
Table 1 The occurrence of other primary cancers in subjected patients with thyroid cancer
No. Age Gender Histopathology Other primary cancers CHEK2 c.470T>C
1 64 female papillary cancer breast cancer TT
2 76 female papillary cancer breast cancer TT
3 65 female follicular cancer breast cancer TC
4 73 female papillary cancer breast cancer TC
5 67 female papillary cancer breast cancer TT
6 73 female papillary cancer breast cancer TT
7 56 female papillary cancer breast cancer TT
8 84 female papillary cancer breast cancer TT
9 62 female papillary cancer breast cancer TT
10 55 female papillary cancer endometrial cancer TT
11 82 female papillary cancer endometrial cancer TT
12 77 female papillary cancer basal cell skin carcinoma TT
13 59 female papillary cancer uterine cervix carcinoma TT
14 73 female follicular cancer mediastinal tumor TT
15 28 female papillary cancer lymphoblastic lymphoma TC
16 74 female papillary cancer renal cancer TT
17 56 female papillary cancer endometrial cancer TT
18 75 female papillary cancer squamous cell tongue carcinoma TC
19 54 female papillary cancer colon carcinoma TT
20 68 female papillary cancer uterine cervix carcinoma TC
21 68 female papillary cancer lung tumor TT
22 79 female papillary cancer vaginal carcinoma TT
23 69 male papillary cancer malignant lymphoma TT
24 67 male papillary cancer lung carcinoma TT
25 32 male papillary cancer salivary gland carcinoma and follicular thyroid carcinoma TT
26 37 male papillary cancer Non-Hodgkin's lymphoma TT
Kaczmarek-Ryś et al. Hereditary Cancer in Clinical Practice  (2015) 13:8 Page 3 of 9The research material was collected between 2008 and
2012, and the majority of patients were newly diagnosed.
The first patients were diagnosed in 2002 and are still
alive. The date of disease onset was set as the date of the
thyroidectomy. Information concerning histopathology
was obtained from three major clinical centers in Poznan:
Greater Poland Cancer Centre, the Regional Hospital in
Poznan and Heliodor Swiecicki Clinical Hospital, where
patients underwent surgery.
Clinical files were established at diagnosis and included
age, histopathological examination results, and the TNM
staging (Table 2).
The control group consisted of 829 unrelated individuals
(562 females and 267 males) randomly chosen from adult
members of families attending diagnostic laboratories in
the Great Poland region for paternity testing. The number
of female controls was doubled as compared to the number
of females in the general population in order to match the
male-to-female ratio in the group of patients with differen-
tiated thyroid carcinoma.All individuals agreed to take part in genetic testing
and the study was approved by the local Ethical Commit-
tee of the Poznań University of Medical Sciences (approval
no. 629/07).
DNA extraction and genotyping
DNA was extracted from whole blood leukocytes using
guanidine isothiocyanate and phenol-chloroform. Isolates
were dissolved in 1xTE buffer and stored at −20°C until
use. The CHEK2 c.470 T > C (rs17879961) genotyping was
performed by pyrosequencing. The sequences of the
primers used in the analysis were designed by PyroMark
Assay Design Software 2.0 (Biotage). The following
primers were used: forward 5’-GCTGGTAATTTGGTCA
TTGTTTT, reverse biotinylated 5’-CATTGCCACTGTG
ATCTTCTAT (PCR product length 142 bp, Tm= 57°C),
and sequencing primer 5’-TGGGTCCTAAAAACTCTT.
Pyrosequencing reactions were performed on the PSQ96
apparatus using PyroMark Gold Q96 reagent kits (Qiagen)
according to the manufacturer’s protocol.
Table 2 Clinical characteristics of thyroid cancer patients
Age groups (range) Number of patients %
0 - 30 80 15
30 - 40 98 18,5
40 – 50 115 21,6
50 - 60 133 25
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Statistical analysis included crude analysis for entire
groups and calculations were adjusted by gender, histo-
logical cancer type and age at disease onset. Hardy-
Weinberg Equilibrium (HWE) was checked for the
c.470 T > C (p.I157T, rs17879961) variant in papillary
thyroid carcinoma and follicular thyroid carcinoma pa-
tients, and in control subjects by chi-square distribution
and Fisher’s exact test. The association between the
c.470 T > C variant and differentiated thyroid carcinoma
occurrence was estimated by calculating the odds ratiosFigure 1 Pyrosequencing profiles of the three genotypes of the c.470
Polymorphic site is marked in yellow.(ORs), 95% confidence intervals (CIs), and p-values
using contingency tables. The independence between the
two variables was verified using Pearson's chi-square
test and Fisher’s exact test. To assess differences in the
probabilities of the occurrence of specific variable level
combinations, the null hypothesis was tested against a
two-sided alternative hypothesis. Statistical significance
was set at p < 0.05. All statistical calculations were per-
formed using the R software v. 3.0.1 [20], a free software
environment for statistical computing and graphics. As
the CC genotype was not present in the studied popula-
tion group, statistical amendment was applied (Review
Manager 5) [21].
Results and discussion
In molecular analysis of fine needle aspiration biopsy
samples, four well known mutant genes have been iden-
tified in papillary and follicular thyroid carcinoma:
BRAF, RAS, RET/PTC, and PAX8/PPARG [22]. However,
while it is possible to identify mutations in DNA from
tumor cells, there is no clear information on other genetic
factors associated with a predisposition to or initiation of a
malignant thyroid transformation. We decided to analyze
the frequency of the CHEK2 c.470C allele in a cohort of
602 Polish differentiated thyroid carcinoma (DTC) cases
and 829 controls using a rapid diagnostic test based on
pyrosequencing technology. It allowed identification of
three possible genotypes: TT, TC and CC (Figure 1).
Our results indicate that the c.470C allele is almost
twice as frequent in thyroid carcinoma patients than in
controls. The analysis of the allele c.470C frequency by
histological type of tumor revealed statistically relevant
differences between patients with papillary thyroid
carcinoma and controls.
Allele c.470C occurred 47 times in 44 patients diagnosed
with papillary thyroid tumors (4.39%), giving the odds ratio
of 1.77 (CI = [1.15-2.70], p = 0.008). In a group of patientsT > C (p.I157T, rs17879961) CHEK2 missense substitution.
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zygotic carriers (5.22%) – the calculated odds ratio is 2.1
[CI = 0.93-4.82], but the latter result is not statistically
significant (p = 0.096) (Table 3).
In an analysis by gender, we observed a strong association
of the c.470C allele frequency with thyroid carcinoma risk
in women with odds ratio of 1.8 (p = 0.001). The female
carriers of this allele (CC or CT genotype) had OR= 1.7
(p = 0.017) for thyroid cancer (Table 3). Being a rare CC
homozygote increased the risk of papillary thyroid carcin-
oma ten-fold (OR = 10.0, C.I. = [0.52-193.90], p = 0.039).
Moreover, a rare homozygous genotype CC was detected
only in 3 women with papillary thyroid carcinoma (0.57%)
and it increased the risk of this cancer type almost thirteen
times compared to that of the general population group
(OR = 12.81, C.I. = [0.66-248.46], p = 0.019).
Our present data do not show any association between
CHEK2 gene variant c.470 T > C and the presence of
DTC in male subjects. However, it may be the result of
lower frequency of differentiated thyroid cancers in
males and it may be related to the small sample size (75
male patients). Studies including larger sample size
would be justified.
Clinical data concerning age at disease onset were
available for 531 patients. We divided the differentiated
thyroid carcinoma patients into five age groups and in-
vestigated the dependence between the age at disease
onset as a categorical variable and the presence of the
c.470C allele. The chi-square statistic was 9.76, which
compared to a χ2 distribution with four degrees of free-
dom, gives a p-value of 0.045. We found a relationship
between the presence of the c.407C genotype and age of
disease onset. The c.407C genotype was more frequent
in differentiated thyroid carcinoma patients diagnosed
between the age of 51 and 60 (OR = 2.2, C.I. = [1.07-4.38]),
and these results were statistically significant (p = 0.016;
Table 4).
An analysis of regional and distant metastases (as defined
by the TNM classification) showed no statistically signifi-
cant correlations with the presence of the c.407C allele
(OR = 1.2, CI = [0.49-3.54], p = 0.694 for regional metasta-
ses, and OR = 1.1, CI = [0.24-9.31], p = 1 for distant metas-
tases). The c.470C allele and multifocality occurred also as
indepent traits (OR = 1, C.I. = [0.44-2.54], p = 0.997).
In differentiated thyroid carcinoma patients, the pres-
ence of the c.470C allele of the CHEK2 gene increased
the risk of developing the disease twice. A relationship
of alterations in the CHEK2 gene with different types of
cancer have been previously reported by others [23-27].
Studies carried out in Finland have shown a relationship
of the c.470C allele with an increased risk of breast can-
cer with an odds ratio of 1.4 [17]. Cybulski and collabo-
rators detected the CHEK2 c.470 T > C alteration at a
frequency of 7.1% (OR = 1.5) in Polish female breastcancer patients. They found an even higher odds ratio
for women diagnosed after fifty years of age [25].
Functionally defective variants of the CHEK2 gene
have been shown to be also linked with an increased
predisposition to colon cancer [26,28]. Three changes in
this gene: IVS2 + 1G > A, 1100delC and c.470 T > C were
previously reported as correlated with a higher risk of
five types of cancer (breast, prostate, colon, thyroid,
kidney) in the Polish population by Cybulski and col-
laborators. However, the thyroid cancer group analyzed
in their study included only 173 patients from the
North of Poland, which seems low given that this is a
frequent cancer, and no data on histopathological types
were provided [12].
To date CHEK2 mutations have been associated with an
increased risk of cancer at several different sites, including
breast, prostate, thyroid, colon, kidney, stomach, (low-
grade) ovarian, bladder, chronic lymphocytic leukemia,
non-Hodgkin’s lymphoma, and a reduced risk of other can-
cers (lung and laryngeal cancer) [12,29-36]. Variant CHEK2
c.470 T >C was also associated with breast cancer in
Poland, Finland, Germany and Belarus. The odds ratio for
breast carcinoma given the I157T mutation was 1.5 in
Poland, 1.4 for the Finnish population, 3.6 in the German
population and 4.5 in the Byelorussian population
[16,17,37]. Our results confirmed also recently published
research from another region of Poland (central Poland)
conducted on a large group of patients with papillary
thyroid cancer, which showed OR= 2.2 (p = 2.37−10) [38].
In accordance with the results published in earlier
reports, we demonstrated that differentiated thyroid
carcinoma is more frequent in women. Among our
patients, females were 7.5 times more likely to develop a
papillary thyroid carcinoma than males. In a group of
patients diagnosed with follicular carcinoma, the male to
female ratio was 1:6. We hypothesized that, due to a
higher risk of thyroid cancer among women, the occur-
rence of allele C may have a prognostic value. Actually,
in our study, the presence of allele C indicated an almost
two-fold increase in the differentiated thyroid carcinoma
risk. A comparison of male differentiated thyroid carcin-
oma patients with men from the control group did not
show statistically significant differences in the frequency
of the alleles and genotypes of CHEK2 gene.
Some earlier studies showed a correlation of this
minor CHEK2 allele c.470C with an early onset of breast
cancer [39,40]. We observed a different trend for thyroid
cancer: the frequency of allele c.470C was increased
more than two-fold in patients who were between 51
and 60 years of age at disease onset (OR = 2.2, C.I. =
[1.07-4.38], p = 0.016). However, in patients who were di-
agnosed at over 60 years of age, the frequency of allele
c.470C was lower with and odds ratio of 0.2 (CI = [0.02-
0.75], p = 0.008) (Table 4). It should also be noted that






TT TC CC Allele positivity(TT vs TC+CC) Total T C Allele frequency
DTC patients: All 602 551 (91,53%) 48 (7,97%) 3 (0,5%) 0.009 1.73 (1.14-2.65) 1204 1150 (95,51%) 54 (4,49%) 0.004 1.81 (1.20-2.72)
By cancer type:
PTC 535 (88,87%) 491 (91,78%) 41 (7,66%) 3 (0,56%) 0.019 1.68 (1.08-2.60) 1070 1023 (95,61%) 47 (4,39%) 0.008 1.77 (1.15-2.70)
FTC 67 (11,13%) 60 (89,55%) 7 (10,45%) n.o. 0.062 2.19 (0.94-5.08) 134 127 (94,78%) 7 (5,22%) 0.096 2.12 (0.93-4.82)
By gender:
DTC females 527 (87,54%) 479 (90,89%) 45 (8,54%) 3 (0,57%) 0.017 1.72 (1.08-2.74) 1082 1031 (95,29%) 51 (4,71%) 0.001 1.80 (1.14-2.82)
DTC males 75 (12,46%) 72 (96%) 3 (4%) n.o. 0.963 0.97 (0.26-3.57) 156 153 (98,08%) 3 (1,92%) 1.009 0.97 (0.27-3.52)
Controls All 829 787 (94,93%) 42 (5,07%) n.o. - - 1658 1616 (97,47%) 42 (2,53%) - -
By gender:
Females 562 (67,8%) 531 (94,48%) 31 (5,52%) n.o. - - 1124 1093 (97,24%) 31 (2,76%) - -
Males 267 (32,2%) 256 (95,88%) 11 (4,12%) n.o. - - 534 523 (97,94%) 11 (2,06%) - -















Table 4 CHEK2 variant c.470C occurrence in patients with differentiated thyroid carcinoma (DTC) in the age groups
due to the age at onset
age group (years) Number of patients Number of patients with genotypes TC+CC (frequency) OR CI p-value
0 - 30 80 7 (8.75%) 1.1 [0.41-2.74] 0.763
30 - 40 98 8 (8.16%) 1.0 [0.40-2.40] 0.918
40 – 50 115 8 (6.96%) 0.8 [0.33-1.92] 0.669
50 - 60 133 17 (12.78%) 2.2 [1.07-4.38] 0.016
60 -100 105 2 (1.9%) 0.2 [0.02-0.75] 0.008
In bold: statistically significant numbers with 95% confidence intervals.
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in order to draw a clear conclusion, an examination of a
larger group in this age range should be performed.
The availability of clinical data allowed us to test a
hypothesis that the rare c.470C allele of the CHEK2 gene
may be correlated with metastases. A statistical analysis
showed that it is not a risk factor for regional or distant
metastases as defined by the TNM classification. We did
not observe any correlation of the presence of this allele
with metastases (OR = 1.4, C.I. = [0.55-4.01], p = 0.496)
or multifocality (OR = 1, C.I. = [0.44-2.54], p = 0.997).
Moreover, in 26 patients, we observed the coexistence
of other primary cancers (Table 2, Figure 2). The mostFigure 2 The occurrence of other primary cancers in patients with thcommon co-morbid was breast cancer (9 patients, 23.4%).
In three patients endometrial cancer was identified (7.8%).
In this group of patients with second primary cancer, allele
c.470C was present in 5 patients (19.2%).
We identified three rare homozygotes among our
patients. Two of them were diagnosed with cancer at a
young age (33 and 34 years), in stage T2. Moreover, one
of those patients had metastases to the submandibular
lymph nodes. In the third patient, the cancer was
detected at the age of 59, in stage T3N1a. Certainly, it is
impossible to reach an unambiguous conclusion on the
impact of the homozygotic state on the disease course
based on three cases but this is an interesting finding,yroid carcinoma.
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to young age thyroid cancer. Actually, the mean cancer
onset age for these homozygotes was seven years lower
than for all female patients in our study.
Conclusions
We have demonstrated that the c.470 T > C substitution
in the CHEK2 gene is associated with an almost two-
fold increase in the risk of papillary thyroid carcinoma
in the Great Poland population, which confirms last
published results for central Poland and earlier research
on Pomeranian population. In homozygous women, it
increases the risk of papillary thyroid carcinoma almost
13-fold. The presence of the c.470C allele significantly
raises the risk of thyroid carcinoma in the midlife, but it
is not a risk factor for the late occurrence of thyroid car-
cinoma. In our opinion, the carriers of the c.470 T > C
alteration in the CHEK2 gene, especially in the homozygous
state, in addition to other cancers, are also at an increased
risk of differentiated thyroid carcinoma. This should be
taken into account by healthcare policymakers. Population
screening for this CHEK2 gene variant should be consid-
ered to be an effective strategy for differentiated thyroid
carcinoma early detection and control.
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